Across TCGA pan-cancer cohorts, IGLJ1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of IGLJ1’s most consistent transcriptional readouts.
The strongest signal is observed in colon adenocarcinoma (COAD), where IGLJ1 RNA is repressed in tumor relative to normal tissue. In most cancer types IGLJ1 is over-expressed in tumor, although a few such as COAD and READ show the opposite, repressed pattern.
COAD, READ, and BRCA are the cancer types where IGLJ1 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLJ1 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.